To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Astex Therapeutics is a biotechnology company focused on the discovery and development of drugs in oncology and other areas. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, UK.
Additional recommended knowledge
The company's research efforts focus on utilization of a proprietary "drug discovery engine" dubbed PyramidTM. Astex has also solved the structure of two key cytochrome P450 isoenzymes involved in drug metabolism, 2C9 & 3A4, which the company hopes will help in optimizing the pharmacokinetic properties and safety of their lead compounds.
Astex's first drug candidate, a cell cycle inhibitor, entered Phase I clinical trials in 2005, and two other candidates are in pre-clinical development.
Carr RA, Congreve M, Murray CW, Rees DC (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10: 987-92.
Congreve M, Murray CW, Blundell TL (2005) Structural biology and drug discovery. Drug Discov Today 10: 895-907.
Williams PA, Cosme J, Vinkovic DM, et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone Science 305: 683-86 (available online by registration at Science website)
Astex Technology: Pioneering Fragment-based Lead Discovery
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Astex". A list of authors is available in Wikipedia.|